General Biologicals Corporation

Equities

4117

TW0004117007

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-07-01 EDT			5-day change	1st Jan Change
22.75 ^TWD	+0.66%		+7.31%	-15.74%

04-30	General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI

General Biologicals Corporation Signs American Laboratory Products Company, Ltd Distribution Agreement

December 17, 2012

General Biologicals Corporation and American Laboratory Products Company Ltd. recently signed a distribution agreement. The partnership allows ALPCO to distribute a line of GBC's Infectious Disease assays for research use only in North America.

Latest news about General Biologicals Corporation

General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
General Biologicals Corporation(TPEX:4117) dropped from S&P Global BMI Index	21-09-20	CI
General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-12	CI
General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
General Biologicals Corporation completed the acquisition of additional 77% stake in Pacgen Life Science Corporation.	20-09-29	CI
General Biologicals Corporation(TPEX:4117) added to S&P Global BMI Index	20-09-21	CI
General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-13	CI
General Biologicals Corporation announced that it has received TWD 77.623729 million in funding from Hong Kong Chlitina International Limited	20-07-22	CI
General Biologicals Corporation entered into a letter of intent to acquire additional 77% stake in Pacgen Life Science Corporation for CAD 1.4 million.	20-07-06	CI
General Biologicals Corporation Announces Develops Covid-19 Testing Solutions for Antigen and Antibody Detection	20-07-06	CI
General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-28	CI
General Biologicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-13	CI
General Biologicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-29	CI
General Biologicals Corporation Adds New Markets for P113 Products Licensed from Pacgen	17-01-24	CI
GBC Introduces its New Discovery Line of Document Cameras	16-11-07	CI
General Biologicals Corporation Makes Significant Progress on PAC-113	16-08-16	CI
General Biologicals Provides Update on Licensed Product, PAC-113	15-10-19	CI
General Biologicals Corporation Signs American Laboratory Products Company, Ltd Distribution Agreement	12-12-17	CI
Pacgen Biopharmaceuticals Corporation cancelled the acquisition of the business and operating assets of CurieMed Corporation from General Biologicals Corporation.	12-03-14	CI

Chart General Biologicals Corporation

Duration

Period

More charts

Company Profile

GENERAL BIOLOGICALS CORP. is a Taiwan-based company principally engaged in the design, development, manufacture, sales and import and export trading of diagnostic kits and auxiliary equipment, as well as the provision of medical technology services. The Company's main products include detection reagents, biological protein new drug, P113, and medical supplies. The Company distributes its products in domestic market and to overseas markets.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENERAL BIOLOGICALS CORPORATION	-15.74%	41.72M
BIOMÉRIEUX	-10.14%	11.38B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-19.13%	6.83B
DIASORIN S.P.A.	+6.18%	5.52B
LANTHEUS HOLDINGS, INC.	+26.61%	5.44B
AUTOBIO DIAGNOSTICS CO., LTD.	-20.49%	3.62B
ANDON HEALTH CO., LTD.	+6.88%	2.56B
10X GENOMICS, INC.	-66.28%	2.26B
MYRIAD GENETICS, INC.	+29.36%	2.24B
VITROLIFE AB	-11.50%	2.13B

Diagnostic & Testing Substances